Biosense Webster News
10 articles
Biosense Webster launches HELIOSTAR™ in Europe, the first radiofrequency Balloon Ablation Catheter, enabling physicians to perform more efficient cardiac ablations
Biosense Webster, Inc., a part of Johnson & Johnson MedTech, has launched the HELIOSTAR Balloon Ablation Catheter in Europe. The catheter is the first radiofrequency balloon ablation catheter and is indicated for use in catheter-based cardiac electrophysiological mapping and ablation. The HELIOSTAR catheter is fully integrated with the CARTO 3 System, a 3D mapping solution, and offers a compliant balloon that can conform to varied pulmonary vein anatomy. It provides the ability to achieve single-shot pulmonary vein isolation in 12 seconds. The launch of the HELIOSTAR catheter is expected to have a positive impact on the growth of Biosense Webster, as it offers an effective and efficient technology for cardiac ablations. The article discusses the benefits of the catheter, including shorter procedure times, reduced fluoroscopy time and exposure, and potential improvements in patient access.
Customers
Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology
Innovative Health lands another catheter reprocessing clearance - Medical Design and Outsourcing
Innovative Health has received FDA clearance to reprocess the Biosense Webster PentaRay Nav eco high-density mapping catheter for reuse. The clearance allows the company to reprocess catheters, potentially saving hospitals thousands of dollars on each atrial fibrillation (AF) procedure. The PentaRay cardiology mapping catheter can do high-resolution mapping and cover all four chambers of the heart. The device was difficult to reprocess in the past because it contains microlumen technology, but Innovative Health has created new protocols and standards to remove blood and Heparin from the microlumen.
CustomersPartners
J&J's Biosense Webster launches cloud-based cardiac ablation data network
The article discusses the terms of use and privacy policy of Questex LLC.
Biosense Webster Launches Report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe
Biosense Webster announces first patients enrolled in post-market approval study for its novel tag-index guided software
Johnson & Johnsons subsidiary, Biosense Webster, has received FDA approval for its VISITAG SURPOINT External Processing Unit. The approval allows for the enrollment of patients in a post-market approval study. The VISITAG SURPOINT Module is designed to simplify and standardize the workflow for ablating patients with paroxysmal atrial fibrillation (PAF). Over 30,000 patients have already been treated with the technology outside the US. The commercialization of the module in the US marks a significant milestone for Biosense Webster.
Customers
Stereotaxis and Johnson & Johnson's Biosense Webster Extend Development Alliance and Supply Agreement
Stereotaxis, Inc. has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson & Johnson’s Biosense Webster, Inc. The amendment ensures the continued global availability of Biosense Webster’s family of commercially-available magnetic ablation catheters, and extends the existing arrangement under which Stereotaxis receives a royalty on the sale of those catheters, through December 31, 2022. The agreement does not modify the current non-exclusive nature of the collaboration.
Partners
Biosense Webster, Inc. Launches Sheath Designed To Reduce Radiation Exposure And Improve Ablation Procedure Efficiency
Biosense Webster, Inc. has announced the availability of its CARTO VIZIGO Bi-directional Guiding Sheath in the United States. This sheath is the first of its kind that can be visualized on the CARTO 3 System during a catheter ablation procedure, reducing the need for fluoroscopy. The sheaths visualization on the system map eliminates the reliance on fluoroscopy to determine its location. This technology aims to improve the care delivered to patients by reducing radiation exposure for both medical staff and patients. The sheath was recently used at Massachusetts General Hospital. Biosense Webster, Inc. is a global leader in diagnosing and treating heart rhythm disorders and is part of the Johnson & Johnson Medical Devices Companies.
Customers
Israel attracts global healthcare giants
The article discusses the impact of acquisitions and expansions of multinational healthcare companies in Israel. It highlights the success stories of Johnson & Johnson Biosense, Philips Healthcare, Edwards Lifescience, Life Technologies, and Merck Serono. These companies have established R&D centers in Israel, contributing to the growth of the local healthcare sector. The companies have also invested in Israeli start-ups, further boosting the countrys healthcare industry.
AcquisitionExpand
Johnson & Johnson Buys Biosense For $400 Mln in Shares
Johnson & Johnson is set to acquire Biosense, a company that develops and manufactures products in the field of cardiology. The acquisition is estimated to be worth $400 million in Johnson & Johnson shares. Biosense will become part of Cordis, a subsidiary of Johnson & Johnson. Biosenses technology allows for accurate mapping and diagnosis of internal organs. Despite being a relatively new company with limited revenue, Johnson & Johnson forecasts that the market for Biosenses products will reach $2 billion.
Acquisition
